两种国产莫索尼定降压疗效的比较

Comparison of Antihypertensive Effect and Safety of Maxonidine for Hypertention From Two Domestic Companies

目的：比较两种国产抗高血压药莫索尼定降压疗效及安全性。方法：采取开放实验，共入选病例６０例，两种国产莫索尼定治疗组各３０例。比较两组患者在服用４周试验药治疗前后血压、心率及生化指标的变化。结果：两组患者治疗后１周血压开始下降，４周后血压明显下降（Ｐ＜０．００１），两组间比较无差异（Ｐ＞０．０５）。两组药物治疗前后心率及生化指标无明显变化。药物不良反应发生率分别为２０％及１６．６７％，均不影响继续治疗，两者比较无显著性差异。结论：两种国产莫索尼定作为新型抗高血压药物，均对轻中度高血压降压效果确切，药物不良反应较少。

OBJECTIVE: To compare effect and safety of moxonidine for hypertention from two domestic companies. METHODS : 60 cases of hypertensive patients were selected for this trial (30 cases for each group). Open clinical trial is needed to analyze the changes of blood pressure, heart rate, blood chemistry and incidence of side effects pre- and post-trial between two groups of patients. RESULTS: The result showed extremely statistical significance in the parameters pre- and post-trial in each group (p<0.001), but no significance between two groups (P>0.05), and the decrease of blood pressure is more than 10%. The heart rate and blood chemistries maintained the same before and after trial. The incidence of adverse reaction were 20% and 16.67%, respectively, but there were no statistical difference between two groups (P>0.05). CONCLUSION: There is no significant difference in antihypertensive effect and safety between moxonidine tablets from the two domestic companies.